Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-ranging study of SAR441566 in moderate to severe Crohn's disease
jRCT2011240067Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Apr 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of balinatunfib in Crohn's disease (4 arms), sponsored by Sanofi. Primary endpoint: Proportion of participants achieving endoscopic response. Started Apr 2025; status: active, not recruiting.
02
Drugs
balinatunfib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2011240067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011240067.